2.70Open2.70Pre Close0 Volume223 Open Interest7.00Strike Price0.00Turnover547.10%IV0.73%PremiumDec 20, 2024Expiry Date2.63Intrinsic Value100Multiplier3DDays to Expiry0.07Extrinsic Value100Contract SizeAmericanOptions Type0.8056Delta0.0530Gamma2.85Leverage Ratio-0.2130Theta0.0004Rho2.30Eff Leverage0.0026Vega
Aurinia Pharmaceuticals Stock Discussion
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced the acceptance of six abstracts at the American Society of Nephrology (ASN) Kidney Week 2024. The data reinforces the clinical importance of LUPKYNIS® (voclosporin) for treating adults with active lupus nephritis (LN). Key highlights include:
...
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
No comment yet